Cytotoxicity testing is the foundational biological safety evaluation required for medical plastics used in medical devices, drug delivery systems, and pharmaceutical packaging. This technical article explains the applicable standards, sample preparation requirements, test methods, acceptance criteria, and regulatory applications of in vitro cytotoxicity testing for medical-grade polymer materials in accordance with ISO 10993-5 and related frameworks.
Technical Overview
Medical plastics—including PVC, polypropylene, polyethylene, polystyrene, polycarbonate, polyurethane, thermoplastic elastomers, and silicone elastomers—are ubiquitous in healthcare because of their processability, sterility compatibility, and chemical resistance. Because these materials make direct or indirect contact with patients, tissues, blood, or drug formulations, they must be demonstrated to be biologically safe before market release. Under the ISO 10993-1 risk management framework, in vitro cytotoxicity testing is positioned as the first-line screening test for essentially all device categories, regardless of contact duration or contact type.
Cytotoxicity testing of medical plastics is performed primarily in accordance with ISO 10993-5 (Tests for in vitro cytotoxicity), with sample preparation governed by ISO 10993-12. In the Chinese regulatory system, the harmonized standard GB/T 16886.5 applies. The test detects toxic effects caused by leachable substances such as residual monomers, oligomers, plasticizers (for example, DEHP in flexible PVC), antioxidants, heat stabilizers, colorants, lubricants, adhesion promoters, and sterilization residues (ethylene oxide or radiolysis products). Commonly used cell lines include L929 mouse fibroblasts, V79 Chinese hamster lung cells, and BALB/c 3T3 cells, which are exposed to test samples or their extracts, after which cell viability, morphology, and growth inhibition are evaluated quantitatively or qualitatively.
Accredited third-party laboratories typically conduct this testing under ISO/IEC 17025 quality systems to support regulatory submissions to authorities such as the FDA, EMA-notified bodies under the EU MDR, and the NMPA.
Testing Samples
Raw Polymer Materials
Unprocessed resins, pellets, granules, and polymer powders submitted for material qualification or supplier change verification. These are tested to establish the intrinsic cytotoxic profile of the base polymer formulation prior to component manufacturing.
Finished and Semi-Finished Components
Molded, extruded, or machined parts in their final representative state, including syringe barrels, luer fittings, catheter shafts, infusion set components, housings, connectors, IV stopcocks, and diagnostic consumables. Both the patient-contacting surface and any secondary finishing (printing, bonding, coating) should be represented.
Films, Sheets, and Tubing
Flexible PVC tubing, multi-layer laminated films for infusion bags, breathable films for wound dressings, blister packaging films, and thermoplastic sheets. Surface-area-based extraction ratios are applied to these thin-walled products.
Sterilized or Post-Processed Parts
Components subjected to the intended sterilization process (ethylene oxide, gamma or e-beam irradiation, steam autoclaving) or secondary operations such as plasma treatment, ultrasonic welding, or solvent bonding. Testing post-processing specimens ensures that sterilant residues and degradation products do not introduce cytotoxic effects.
Testing Items
The scope of cytotoxicity evaluation for medical plastics typically includes the following items:
- Extract (elution) cytotoxicity testing using polar and non-polar extraction media
- Direct contact cytotoxicity testing for materials with intended tissue contact
- Indirect contact cytotoxicity testing by agar diffusion or filter diffusion
- Quantitative cell viability assessment by MTT, XTT, WST-8, or neutral red uptake (NRU) assays
- Qualitative morphological grading of cell lysis, rounding, detachment, and vacuolization
- Qualitative and quantitative interpretation against the ISO 10993-5 reactivity grading system
Testing Methods
Extract (Elution) Method with MTT Assay
The extract method is the most widely applied approach for medical plastics because it simulates leachable release under clinically exaggerated conditions. Samples are prepared per ISO 10993-12 at a standard ratio of 0.1 g of material per mL of extraction medium (or 6 cm²/mL for surfaces between 0.5 mm and 1 mm in thickness, and 3 cm²/mL for thicker specimens). Extraction is performed in serum-supplemented minimum essential medium (MEM) or physiological saline using one of the following standard conditions:
- 37 °C for 24 ± 2 hours (physiological simulation)
- 50 °C for 72 ± 2 hours (accelerated extraction)
- 70 °C for 24 ± 2 hours (accelerated extraction)
- 121 °C for 1 ± 0.2 hours (exaggerated extraction)
The resulting extract is applied to cultured L929 fibroblast monolayers for 24 hours. Cell viability is then quantified colorimetrically using the MTT tetrazolium reduction assay, in which metabolically active cells convert MTT to formazan, and absorbance is measured at 570 nm. Viability is expressed as a percentage of the blank control, with the widely accepted pass criterion being viability greater than or equal to 70%.
Direct Contact Method
In the direct contact method, a sterile test specimen of defined area is placed gently onto or beneath a sub-confluent cell monolayer and incubated for 24 to 48 hours. This method is appropriate for low-density materials and elastomeric components that do not mechanically damage the monolayer. Cytotoxicity is assessed by microscopic examination of the zone of reduced cell density, morphological changes, and lysis beneath and around the specimen.
Agar Diffusion and Filter Diffusion Methods
In the agar overlay (indirect contact) method, cells are covered with a thin layer of nutrient agar before the specimen is placed on the agar surface, allowing diffusible leachables to reach the cells while preventing mechanical trauma. The filter diffusion method places a cellulose acetate membrane between the cell layer and the specimen, and is suitable for evaluating materials that release toxicants rapidly. Both methods rely on microscopy to score the zone of lysis or decolorization.
Interpretation Criteria
Qualitative reactivity is graded on a five-point scale as defined in ISO 10993-5: Grade 0 (none, no detectable zone), Grade 1 (slight, zone limited to under the specimen), Grade 2 (mild, zone extending less than 0.5 cm beyond the specimen), Grade 3 (moderate, zone extending 0.5 to 1.0 cm), and Grade 4 (severe, zone extending more than 1.0 cm). For quantitative assays, if cell viability falls below 70% of the blank, the sample is considered to have a cytotoxic potential, and follow-up chemical characterization per ISO 10993-18 is generally recommended to identify the causative leachable.
Applications
Cytotoxicity testing of medical plastics supports multiple quality, regulatory, and development objectives across the medical product lifecycle:
- Regulatory submissions for device registration, including FDA 510(k) and PMA files, EU MDR technical documentation, and NMPA registration dossiers, where cytotoxicity data is a mandatory element of the ISO 10993-1 biological evaluation plan
- Biocompatibility screening of candidate polymers, masterbatch formulations, colorants, and additives during material selection and R&D
- Change control evaluation when substituting resin grades, suppliers, molding parameters, or sterilization modalities
- Verification of pharmaceutical packaging systems for parenteral and ophthalmic preparations, often aligned with USP <87> and USP <88> plastics classification requirements
- Routine quality control and lot release testing for high-risk single-use components such as infusion sets, syringes, and blood-contacting consumables
- Support of sterilization validation by confirming that ethylene oxide residuals or irradiation degradation products remain within biologically safe limits
FAQ
Which standards govern cytotoxicity testing of medical plastics?
The primary standard is ISO 10993-5 for in vitro cytotoxicity, supported by ISO 10993-12 for sample preparation and reference materials. The harmonized Chinese national standard GB/T 16886.5 is equivalent for NMPA submissions. For pharmaceutical packaging plastics, USP <87> is frequently applied, and ASTM F813 and ASTM F895 provide additional direct and indirect contact methodologies.
What is the pass criterion for the MTT extract test?
A test article passes when the mean cell viability of the sample extract group is greater than or equal to 70% of the blank control. Viability between 50% and 70% is generally considered slightly cytotoxic and requires a case-by-case risk assessment, while values below 50% indicate definite cytotoxic potential.
How much sample is required for testing?
Most laboratories request the equivalent of approximately 5 to 10 grams of material or a sufficient number of finished components to provide at least 60 cm² of contact surface. This allows preparation of triplicate extracts in both polar and non-polar media, including positive and negative controls.
Which extraction condition should be selected?
The extraction condition is chosen based on the intended clinical use and the physical tolerance of the material. The 37 °C for 24 hours condition simulates physiological exposure and is suitable for most finished devices, while 50 °C or 70 °C conditions provide accelerated extraction for material screening. The 121 °C condition is reserved for materials that must withstand such temperatures without deformation or degradation.
How long does the test take?
For a standard quantitative MTT extract test, the laboratory workflow—including cell culture, extraction, exposure, and viability measurement—typically requires 10 to 15 working days. Turnaround may extend to three or four weeks when combined with additional endpoints or repeat testing for verification.
Can a cytotoxicity test replace the full biocompatibility panel?
No. Cytotoxicity is a screening test that must be integrated into a risk-based biological evaluation plan covering sensitization, irritation or intracutaneous reactivity, systemic toxicity, and material-specific endpoints defined in the ISO 10993 series, determined by the nature, duration, and degree of body contact of the device.
What should be done if a medical plastic fails the cytotoxicity test?
A failed result should trigger extractable and leachable chemical characterization per ISO 10993-18 to identify the responsible substance, commonly a plasticizer, stabilizer, colorant, adhesive, or sterilant residue. Formulation adjustment, process optimization, or a change of sterilization method can then be evaluated, followed by retesting to confirm improved biocompatibility.